Related Experiment Video
Updated: Aug 15, 2026
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Antagonists of Hsp16.3, a low-molecular-weight mycobacterial chaperone and virulence factor, derived from
Abhik Saha1, Archna Sharma, Amlanjyoti Dhar
1Bose Institute, Department of Microbiology, P1/12 C.I.T. Scheme VIIM, Calcutta 700054, India.
Abstract:
The persistence of Mycobacterium tuberculosis is a major cause of concern in tuberculosis (TB) therapy. In the persistent mode the pathogen can resist drug therapy, allowing the possibility of reactivation of the disease. Several protein factors have been identified that contribute to persistence, one of them being the 16-kDa low-molecular-weight mycobacterial heat shock protein Hsp16.3, a homologue of the mammalian eye lens protein alpha-crystallin. It is believed that Hsp16.3 plays a key role in the persistence phase by protecting essential proteins from being irreversibly denatured. Because of the close association of Hsp16.3 with persistence, an attempt has been made to develop inhibitors against it. Random peptide libraries displayed on bacteriophage M13 were screened for Hsp16.3 binding. Two phage clones were identified that bind to the Hsp16.3 protein. The corresponding synthetic peptides, an 11-mer and a 16-mer, were able to bind Hsp16.3 and inhibit its chaperone activity in vitro in a dose-dependent manner. Little or no effect of these peptides was observed on alphaB-crystallin, a homologous protein that is a key component of human eye lens, indicating that there is an element of specificity in the observed inhibition. Two histidine residues appear to be common to the selected peptides. Nuclear magnetic resonance studies performed with the 11-mer peptide indicate that in this case these two histidines may be the crucial binding determinants. The peptide inhibitors of Hsp16.3 thus obtained could serve as the basis for developing potent drugs against persistent TB.
Insights
Researchers identified peptide inhibitors targeting Mycobacterium tuberculosis Hsp16.3, a protein crucial for persistent infections. These peptides inhibit its chaperone activity, offering a potential new strategy for tuberculosis drug development.
Area of Science:
- Microbiology
- Drug Discovery
- Structural Biology
Background:
- Mycobacterium tuberculosis persistence is a significant challenge in tuberculosis therapy, enabling drug resistance and disease reactivation.
- The 16-kDa heat shock protein Hsp16.3 is implicated in persistence by preventing essential protein denaturation.
- Hsp16.3 is a homolog of mammalian alpha-crystallin, suggesting potential therapeutic targets.
Purpose of the Study:
- To identify and characterize inhibitors of the Mycobacterium tuberculosis Hsp16.3 protein.
- To explore the potential of these inhibitors as a basis for novel anti-tuberculosis drugs targeting persistent bacteria.
Main Methods:
- Screening of random peptide libraries displayed on bacteriophage M13 to identify Hsp16.3 binders.
- In vitro assays to assess the binding affinity and chaperone inhibitory activity of identified peptides.
- Nuclear magnetic resonance (NMR) studies to elucidate peptide-protein interactions and identify key binding determinants.
Main Results:
- Two phage clones yielding binding peptides (11-mer and 16-mer) were identified.
- Synthetic peptides demonstrated dose-dependent binding to Hsp16.3 and inhibition of its chaperone activity.
- Peptides showed specificity, with minimal effect on the homologous human alphaB-crystallin protein.
- NMR studies suggested two histidine residues in the 11-mer peptide are critical for binding.
Conclusions:
- Peptide inhibitors targeting Hsp16.3 were successfully developed.
- These inhibitors exhibit specificity and effectively block Hsp16.3 chaperone activity.
- The identified peptide inhibitors represent a promising foundation for developing new drugs against persistent tuberculosis infections.
